Pretraga

Rezultati

DMSO causes induction of transiently transfecting rat beta(miny)(b)-globin promoter in nonerythroid cells [1996]

Mitrović, T; Pavlović, S ; Zarić, J; Popović, Z

IPO-trimethylation of histone H3-lysine(9) associated with P210BCR-ABL tyrosine kinase of chronic myeloid leukaemia [2008]

Mancini, Manuela; Zuffa, Elisa; Veljković, Nevena V. ; Brusa, Gianluca; Corrado, Patrizia; Corradi, Valentina; Martinelli, Giovanni; Barbieri, Enza; Santucci, Maria Alessandra

COVID-19 disease in patients with chronic neutropenia: The experience from the European Network for Innovative Diagnosis and Treatment of Chronic Neutropenias [2024]

Spanoudakis, Michail; ...; Kapor, Suncica; ...; (broj, koautora 20)

MajesTEC-4: Phase 3 trial of Teclistamab plus Lenalidomide versus Lenalidomide in patients with newly diagnosed multiple myeloma [2023]

Cook, Gordon; ...; Bila, Jelena S. ; ...; (broj koautora 22)

HELIOS action: Advancing research, education, and equity in haemoglobinopathies across Europe and beyond [2025]

Chatzimatthaiou, Sotiroula; Antic, Darko; ...; (broj, koautora 23)

An analysis of rat beta(miny)-globin gene promoter [1998]

Mitrović, T; Pavlović, S ; Popović, Z

Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura [2010]

Lotta, Luca Andrea; Mariani, Mariagabriella; Consonni, Dario; Mancini, Ilaria; Palla, Roberta; Maino, Alberto; Vucelic, Dragica A ; Pizzuti, Michele; Mannucci, Pier Mannuccio; Peyvandi, Flora

Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy [2022]

Voso, Maria-Teresa; ...; Dencic-Fekete, Marija; ...; (broj, koautora 24)

Incubation of murine bone marrow cells in hypoxia ensures the maintenance of marrow-repopulating ability together with the expansion of committed progenitors [2000]

Ivanovic, Zoran B; Bartolozzi, B; Bernabei, PA; Cipolleschi, MG; Rovida, E; Milenkovic, Pavle B; Praloran, Vincent; Dello, Sbarba P

Pharmacokinetics (PK), safety and overall response rate (ORR) achieved with subcutaneous (SC) administration of rituximab in combination with chemotherapy were comparable to those achieved with intravenous (IV) administration in patients (pts) with follic [2013]

Davies, AJ; Merli, Francesco; Mihaljevic, Biljana S ; Siritanaratkul, Noppadol; Solal-Celigny, Philippe; Boehnke, Axel; Berge, Claude; McIntyre, Christine; Barrett, M; MacDonald, D